Please use this identifier to cite or link to this item:
|Title:||Discovery of [F-18]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.|
Positron computed tomography
|Publisher:||American Chemical Society|
|Citation:||Greguric, I., Taylor, S. R., Denoyer, D., Ballantyne, P., Berghofer, P., Roselt, P., Pham, T.Q., Mattner, F., Bourdier, T., Neels, O. C., Dorow, D.S., Loc'h, C., Hicks, R. J., & Katsifis, A. (2009). Discovery of [f-18]n-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. Journal of Medicinal Chemistry, 52(17), 5299-5302. doi:10.1021/jm9008423|
|Abstract:||The high melanoma uptake and rapid body clearance displayed by our series of [123I]iodonicotinamides prompted the development of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide ([18F]2), a novel radiotracer for PET melanoma imaging. Significantly, unlike fluorobenzoates, [18F]fluorine incorporation on the nicotinamide ring is one step, facile, and high yielding. [18F]2 displayed high tumor uptake, rapid body clearance via predominantly renal excretion, and is currently being evaluated in preclinical studies for progression into clinical trials to assess the responsiveness of therapeutic agents. © 2009, American Chemical Society|
|Gov't Doc #:||1520|
|Appears in Collections:||Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.